Enter your email address in the box to the right of this page to receive email updates from the Life Sciences Hub when new content is published.
For those with an interest in life sciences, the rise to prominence of CRISPR, a transformational development in the field of molecular biology and genetics, has been impossible to ignore.
Welcome to our blog dedicated to Life Sciences. We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector. We focus on (bio)pharmaceuticals and medical technologies, and also cover food and beverages, cosmetics and other healthcare products.
14 September 2020 - Posted by: Lars Braams
As per 8 September 2020, 143 search results containing the words “Covid 19” in the title, claims or the abstract of a patent show up in the international patent database Espacenet. Over the past weeks, this number grows with about 15 new results each week. While the race for a vaccine covers the headlines around › Read More
24 August 2020 - Posted by: Jeanne Fabre
The two long-awaited orders of the French anti-gift regulation were finally published on 14 August 2020 (see our previous blog post: Decree on French anti-gift regulation published): Order of 7 August 2020 setting the amounts from which an agreement provided for in Article L1453-8 of the Public Health Code and specifying the granting of benefits › Read More
12 August 2020 - Posted by: Isabel Rutten
In June 2020, the Dutch House of Representatives passed an Emergency Act to temporarily amend the Dutch Patent Act, allowing patent holders and applicants more time to secure and preserve their patents. Before the introduction of the Emergency Act, the Covid-19 pandemic may have affected companies that owned patents or were in the process of › Read More
05 August 2020 - Posted by: Jeanne Fabre
At the end of the Conventional Policy Steering Committee held on 23 July 2020, the French Pharmaceutical Companies Association (Leem) and the French Economic Committee for Health Products (CEPS) agreed to an extension of their Framework Agreement, which is the reference framework for fixing and regulating medicines pricing in France. The agreement, which would have › Read More
03 August 2020 - Posted by: Tine Carmeliet
Recently, Royal Decree no 34 was published, containing measures to ensure the availability and proper management of medicinal products during the Covid-19 pandemic. The royal decree enables the Minister of Health to authorise a product from Belgium’s strategic stockpile of medicinal products that is not licensed for the treatment of Covid-19 to be used for › Read More